Combining a lifelong passion for science and business with personal experiences can fuel groundbreaking innovations in cancer therapy. In this episode, Brad Niles, CEO of ARIZ Precision Medicine, shares his entrepreneurial journey, from quirky early ventures like breeding mice and wedding pigeons to co-founding a biotech company. Motivated by a personal connection to cancer, he discusses ARIZ’s development of siRNA-based therapies targeting genetic drivers like the Prdm2 gene in lung cancer, aiming for precision treatment with fewer side effects. Brad reflects on the challenges of biotech entrepreneurship, including securing funding, building expert networks, and working within regional innovation ecosystems. He also explores regulatory shifts, drug pricing complexities, and how environmental and demographic changes are reshaping cancer trends. Tune in to explore the journey from early ventures to cutting-edge cancer therapies, and discover the power of resilience, networking, and precision medicine in shaping the future of cancer care! Resources: Connect with and follow Brad Niles on LinkedIn. Follow ARIZ on their LinkedIn and visit their website. Email Brad directly here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related